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Abstract 
Ultrasound-triggered drug-loaded microbubbles have great potential for drug delivery due to their 
ability to locally release drugs and simultaneously enhance their delivery into the target tissue. We 
have recently shown that upon applying ultrasound, nanoparticle-loaded microbubbles can deposit 
nanoparticles onto cells grown in 2D monolayers, through a process that we termed “sonoprinting”. 
However, the rigid surfaces on which cell monolayers are typically growing might be a source of 
acoustic reflections and aspherical microbubble oscillations, which can influence microbubble-cell 
interactions. In the present study, we aim to reveal whether sonoprinting can also occur in more 
complex and physiologically relevant tissues, by using free-floating 3D tumor spheroids as a tissue 
model. We show that both monospheroids (consisting of tumor cells alone) and cospheroids 
(consisting of tumor cells and fibroblasts, which produce an extracellular matrix) can be sonoprinted. 
Using doxorubicin-liposome-loaded microbubbles, we show that sonoprinting allows to deposit large 
amounts of doxorubicin-containing liposomes to the outer cell layers of the spheroids, followed by 
doxorubicin release into the deeper layers of the spheroids, resulting in a significant reduction in cell 
viability.  Sonoprinting may become an attractive approach to deposit drug patches at the surface of 
tissues, thereby promoting the delivery of drugs into target tissues.    
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Despite the wide range of anti-cancer agents available, successful clinical treatment of tumors remains 
challenging. One of the major reasons is the severe toxicity that can occur in healthy tissues due to the 
non-selective nature of anti-cancer drugs. An attractive solution is to encapsulate these drugs into 
nanometer-sized particles to localize their therapeutic effect. Nanomedicines are believed to 
preferably extravasate in tumorous tissue based on the enhanced permeation and retention (EPR) 
effect1,2. This selective uptake originates from enlarged openings in the poorly-organized endothelial 
barriers of fast growing tumors, and inefficient removal of products due to underdeveloped lymph 
vessels. However, the EPR effect has proven to be tumor type- and patient-dependent and can even 
be highly variable within a  tumor2–5. Furthermore, tumor-associated fibroblasts can produce a very 
dense extracellular matrix, limiting the penetration of nanoparticles in the deeper layers of the 
tumor2,6–8. These factors are often ill-represented in preclinical tumor models, which could explain why 
so far only limited therapeutic benefits of nanomedicines are found in clinical studies5,9,10.  
Nanomedicines remain, however, very attractive due to their tunable nature; their ability to (i) improve 
the solubility and plasma half-life of (poorly soluble) drugs and (ii) protect bioactive substances, such 
as proteins and genetic drugs, from premature degradation while  promoting their cellular uptake via 
endosomal pathways. To improve the intratumoral uptake of nanomedicines, active targeting 
approaches are currently under investigation11–13. Using physical triggers to achieve active nanoparticle 
delivery is of particular interest since it does not require the presence of specific ligands and it is not 
affected by changes in target expression. Possible physical stimuli that could induce local drug delivery 
include magnetism, thermal activity, light and ultrasound2,13,14. 
Here, we focus on ultrasound-triggered drug delivery since ultrasound is a well-known, cost-effective 
and relatively safe method amenable to both imaging and therapy. In contrast-enhanced ultrasound 
imaging the blood pool is infused with lipid-shelled micron-sized gas bubbles, named microbubbles, 
which respond to ultrasound by cavitating, i.e. expanding and contracting along with the pressure 
phases of the ultrasound wave15–17. The strong echo arising from cavitation makes microbubbles 
excellent contrast agents for imaging. Additionally, microbubbles are under investigation as drug 
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carriers, since ultrasound-induced cavitation can facilitate spatial and temporal control of drug release 
and has shown to promote the uptake of drugs and nanoparticles in cells and tissues15. Until recently, 
two main mechanisms were commonly believed to be responsible for this improved delivery: firstly,  
sonoporation, i.e. the formation of small pores in cell membranes and opening of tight junctions and, 
secondly, enhanced endocytosis15,18,19. We and others however showed that loading nanoparticles 
onto the microbubble shell can significantly improve their cellular uptake when compared to simply 
mixing these nanoparticles with microbubbles20–24. Since neither sonoporation, nor enhanced 
endocytosis could explain this, it was suggested that an alternative mechanism might be at play. In an 
earlier study25, we introduced ‘sonoprinting’ as a mechanism to explain this observation. We found 
that nanoparticle-loaded microbubbles release their payload along with parts of the microbubble shell 
during cavitation, after which the translating microbubble gas core drags the nanoparticles in its wake 
and finally deposits them onto the cell membrane, hence the term sonoprinting (figure 1). Only 
recently, we elucidated the biophysical microbubble-cell interactions that are responsible for 
sonoprinting and identified the optimal acoustic settings to induce it26. This study was however 
performed on adherent cells cultured on a stiff membrane in a static in vitro setup, which can impact 
the observed microbubble behavior. Indeed, it has been shown that the presence of a solid boundary 
can cause aspherical microbubble oscillations, which may influence their interaction with the cells27–
29. Furthermore, since sonoprinting was only studied on a single cell layer, questions on the significance 
of sonoprinting in a more physiologically relevant model remained. For these reasons, we investigate 
in the current study whether sonoprinting can also stimulate drug delivery in 3D tumor spheroids. 
 
Figure 1: The mechanism of sonoprinting. Reproduced from Roovers et al. Biomaterials, 2019, with permission from Elsevier. 
Compared to 2D cell monolayers, spheroids mimic the in vivo conditions more closely due to the 
enhanced cell-to-cell contact, while maintaining the controlled environment of an in vitro study30–32. 
Additionally, they can resemble the clinical situation even more by including multiple cell types that 
are typically found in the tumor microenvironment, such as tumor-associated fibroblasts and immune 
cells5,8,32–34. The 3D micro-environment in such cultures resembles clinical avascular tumor nodules, as 
an extracellular matrix is formed that may act as a major physical barrier for drug penetration31. 
Indeed, research has revealed that several treatments are less effective in 3D multicellular spheroids 
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than in 2D monolayer cultures, due to limitations in drug diffusion and due to the variable proliferative 
state of the cells in a 3D environment30,31,35,36.  
The aim of the current study is to investigate whether nanoparticle-loaded microbubbles and 
ultrasound can promote the delivery and cytotoxicity of drug-loaded nanoparticles into tumor 
spheroids. As such, we aim to verify whether sonoprinting can also occur in a complex tissue. We made 
use of 3D spheroids consisting of either tumor cells alone (monospheroids) or tumor cells cocultured 
with fibroblasts (cospheroids) to mimic the effect of tumor stroma. First, fluorescent polystyrene beads 
and ‘empty’ fluorescently labeled liposomes were coupled onto microbubbles and exposed to 
ultrasound to investigate if sonoprinting of beads/liposomes on 3D spheroids could be achieved. 
Afterwards, we prepared microbubbles loaded with doxorubicin-loaded liposomes (resembling either 
Doxil® or ThermoDOX®) to study drug release from the sonoprinted liposomes and the associated 
cytotoxic effects on the spheroids. 
Materials and methods 
Cell culture 
4T1 murine breast cancer cells (ATCC, Manassas, VA, USA), 4T1 Luciferase positive cells (courtesy of 
the lab of Prof. Olivier De Wever) and NIH/3T3 fibroblast cells (ATCC) were grown in culture flasks in a 
humidified atmosphere with 5% CO2 at 37°C. The culture medium for the 4T1 cells was RPMI (Gibco™, 
Thermo Fisher Scientific, Waltham, WA, USA), supplemented with 10% (v/v) fetal bovine serum 
(Hyclone, Thermo Fisher Scientific, MA, USA), 20 U/mL penicillin-streptomycin (Gibco™) and 2 mM L-
glutamine (Gibco™). For the NIH/3T3 cells, Dulbecco’s Modified Eagle Medium (Gibco™), with the 
same supplements was used.  
Spheroid culturing and characterization 
Multicellular tumor spheroids were made by harvesting NIH/3T3 and 4T1 cells using 0.25% (w/v) 
Trypsin - EDTA solution (Gibco™) and transferring them to a custom-made, agarose-based 400 µm 
microwell array, developed by the Rivron Lab (MERLN institute, Maastricht, The Netherlands)37,38.  One 
microwell array chip was able to form 1500 spheroids, containing approximately 500 cells per spheroid. 
The microwells were either filled with 4T1 cells only (monospheroids) or NIH/3T3 and 4T1 cells in a 5:1 
ratio (cospheroids), in accordance with previous work7. The cells were allowed to self-aggregate for 
48h to form spheroids. After 48h, medium was removed and the spheroids were flushed out using 
fresh medium before being transferred to acoustically-transparent Lumox dishes (Sarstedt AG & Co. 
KG, Nümbrecht, Germany) that were sealed with water-impermeable acoustically transparent 
Sonolids, developed by the BUBBL group (Institute of Biomedical Engineering, Oxford University, UK)39. 
One dish was filled with approximately 1500 spheroids, suspended in 5 mL full medium. The cellular 
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organization of the NIH/3T3 and 4T1 cospheroids was examined by labeling NIH/3T3 cells with 
CellTrace™ Blue (excitation/ emission maxima: 355⁄410 nm, Molecular Probes™, Thermo Fisher 
Scientific, Waltham, WA, USA) and 4T1 cells with CellTrace™ Yellow (excitation/ emission maxima 
546⁄579 nm, Molecular Probes™) prior to spheroid formation.  
Microbubbles 
Biotinylated microbubbles were composed of DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) 
(Avanti Polar Lipids, Alabaster, AL, USA) and DSPE-PEG3400-biotin (1,2-distearoyl-sn-glycero-3-
phosphoethanol-amine-N-(biotinyl(polyethyleneglycol)-3400)) (Laysan Bio Inc, Arab, AL, USA) in a 
molar ratio of 85:15. Microbubbles without biotin were prepared as control samples (coadministration 
of microbubbles and liposomes) and were composed of DPPC  and DSPE-PEG2000 (1,2-distearoyl-sn-
glycero-3-phosphoethanol-amine-N-[(polyethyleneglycol)2000) (Laysan Bio Inc, Arab, AL, USA) in the 
same molar ratio. The microbubbles were prepared as described before18,25,40. In short, appropriate 
amounts of the lipids were dissolved in chloroform and transferred to a round bottom flask. After 
evaporation of the chloroform using a rotavapor at 65°C, the resulting lipid film was rehydrated in a 
preheated mixture of HEPES buffer (20 mM, pH 7.4), propylene glycol, and glycerol (ratio 7:2:1) to yield 
a final lipid concentration of 0.75 mg/mL. Aliquots of this lipid solution were transferred into 2.5 mL 
chromatography vials, of which the headspace was filled with inert C4F10 gas (F2 chemicals, Preston, 
UK). Finally, microbubbles were obtained by high speed shaking of the lipid solution for 15s in a 
Capmix™ device (3 M-ESPE, Diegem, Belgium). The microbubbles were subsequently washed by 
centrifugation (750 g for 5 min at room temperature) using HEPES buffer. Afterwards, avidin (100 
mg/mL, IBA GmbH, Göttingen, Germany) was added in excess and left to incubate for 5 min to couple 
to the biotin groups. The excess of avidin was removed by 2 cycles of centrifugation and finally the 
microbubbles were resuspended in HEPES buffer at a concentration of 109 microbubbles/mL, as 
determined by a Coulter Counter (Multisizer 4, Beckman Coulter Life Sciences, Indianapolis, IN, USA). 
Biotinylated polystyrene beads 
To evaluate the delivery of inert nanoparticles, yellow-green fluorescent carboxylate-modified 
polystyrene beads of 100 nm in size (excitation/emission: 505/515 nm, Molecular Probes™, Waltham, 
WA, USA) were coupled to the microbubble surface. To attach the beads to the biotinylated 
microbubble surface, the beads were covalently coated with polyethylene glycol-biotin via amine-
coupling as described before25. To this end, 2 kDa biotin-PEG-amine (Creative PEGWorks, Winston 
Salem, NC, USA), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) (Sigma 
Aldrich, Saint Louis, MO, USA), and N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) (Sigma-Aldrich) 
were dissolved in HEPES Buffered Saline (HBS) (10 mM HEPES (Sigma-Aldrich), 150 mM NaCl (Sigma-
Aldrich) containing 3.4 mM EDTA (Merck, Overijse, Belgium), 0.005% Tween 20 (Sigma-Aldrich) and 
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adjusted to pH 8). The fluorescent beads were added to this mixture to give final concentrations of 4 
mg/mL EDC, 1.13 mg/mL Sulfo-NHS, 10 mg/mL biotin-PEG-amine and 1% w/V beads. The mixture was 
rotated overnight at room temperature. The PEG-biotin modified beads were purified by 
ultracentrifugation (Beckman Coulter Life Sciences) at 234000 g for 45 min and resuspended in HBS 
buffer to yield a concentration of 2% w/V beads. Afterwards, the zeta potential was measured by the 
Zetasizer Nano SZ (Malvern Panalytical) where an increase in the zeta potential of the negatively 
charged beads indicated partial shielding of the charge by the polymer coating and successful PEG-
biotin coating.  
Biotinylated liposomes  
Regular liposomes were based on Doxil® and consisted of DPPC, DSPE-PEG3400-biotin and cholesterol 
(Avanti Polar Lipids) in a molar ratio of 55:5:40, as previously reported by Lentacker et al.24. 
Thermosensitive liposomes were based on ThermoDOX® and consisted of DPPC, DSPE-PEG3400-biotin 
and MSPC (1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine) (Avanti Polar Lipids) in a molar ratio 
of 85:5:10, as previously reported by Van Elk et al.41. 1 mol% of DiD (excitation/emission: 648/670 nm; 
Molecular Probes™, Thermo Fisher Scientific, Waltham, WA, USA) was added to the lipid mixture to 
fluorescently label the liposomes. Liposomes were prepared by transferring appropriate amounts of 
lipids dissolved in chloroform to a round bottom flask. Chloroform was removed via evaporation and 
HEPES buffer (20 mM, pH 7.4) was added to rehydrate the lipid film, resulting in a lipid concentration 
of 16 mg/mL. To reduce the liposome size, the lipid solution was sonicated in a bath sonicator (Branson 
Ultrasonics, Emerson, St. Louis, MO, USA) for 5 min. The final liposome size was determined on a 
Zetasizer Nano SZ (Malvern Panalytical, Worcestershire, UK).  
Doxorubicin-loaded liposomes (DOX-liposomes) were prepared in the same way, but were 
resuspended in (NH4)2SO4 buffer (250 mM, pH 5.5) for active loading of doxorubicin into the 
liposomes42. Afterwards, the external (NH4)2SO4 buffer was removed via ultracentrifugation (L8-70M 
ultracentrifuge equipped with a SW55Ti Rotor, Beckman Coulter Life Sciences) at 35 000 rpm for 1h at 
25°C for the regular DOX-liposomes; and via PD-10 columns (Sephadex G-25, GE Healthcare Life 
Sciences, Pittsburgh, PA, USA) in case of thermosensitive DOX-liposomes. Subsequently, a doxorubicin 
solution (10 mg/mL) was added to the liposomes in a 1:10 volume ratio and left to incorporate in the 
liposomes for 2h at 70°C in case of the regular liposomes and at 37°C in case of the thermosensitive 
liposomes. To remove the excess of free doxorubicin, a second ultracentrifugation step (35 000 rpm, 
1h, 25°C) was performed and the DOX-liposomes were finally resuspended in HEPES buffer. The 
doxorubicin concentration in the liposomal dispersions was measured on an EnVision 
spectrophotometer (absorbance at 450 nm, Perkin-Elmer, Zaventem, Belgium). Therefore the 
liposomes were incubated with 10% Triton X-100 to release the doxorubicin from the DOX-liposomes 
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and the signal was compared to a calibration curve of doxorubicin solutions with known 
concentrations, in the presence of 10% Triton X-100.  Furthermore, the concentration of liposomes 
(i.e. number of liposomes per mL) was determined using a NanoSight LM10 system (Malvern 
Panalytical). Knowing the doxorubicin concentration and the number of liposomes per mL of the 
liposomal dispersions, we were able to estimate the amount of doxorubicin per liposome.  
Loading microbubbles with polystyrene beads/liposomes 
To load the polystyrene beads/liposomes on the surface of the microbubbles, 50 µL of the biotinylated 
polystyrene beads or liposomes was added to 1 mL of the avidinylated microbubbles and allowed to 
incubate for 5 min. For the liposome-loaded microbubbles, the coupling efficiency was determined by 
measuring the concentration of free liposomes remaining in the liposome-microbubble dispersion, 
using the NanoSight LM10.  
Ultrasound treatment of tumor spheroids 
Ultrasound exposure experiments were performed in a water bath (37 °C) containing a rubber bottom 
layer to prevent reflections of the ultrasound beam (figure 2A). 100 µL of bead-loaded or liposome-
loaded microbubbles was added to the Lumox plates containing approximately 1500 spheroids in 
suspension. The Lumox plates were radiated for 10s using a Sonitron device (Sonitron 2000; Rich-Mar, 
Inola, OK, USA) with a 1 MHz center frequency, at 2 W/cm² (corresponding to 700 kPa peak negative 
pressure), 10% duty cycle and 2000 cycles per pulse (figure 2B). In our previous work on 2D monolayers 
of cells, we found that these are optimal acoustic settings to achieve sonoprinting25,26. Following the 
ultrasound treatment, the Lumox plates were left to incubate in the cell incubator for 4h before 
analysis. A number of control samples were included as well. First, a “coadministration” sample, in 
which a physical mixture of 5 µL polystyrene beads or liposomes and 100 µL non-biotinylated 
microbubbles was transferred to the Lumox plates, followed by ultrasound treatment as described 
above. A second control contained 5 µL polystyrene beads (“bead only”) or liposomes (“liposome 
only”) and was not exposed to ultrasound. In the experiments where doxorubicin was encapsulated in 
the liposomes, a third “doxorubicin only” control was included, in which free doxorubicin was added 
to the Lumox plate in the same concentration as in the other samples containing doxorubicin, without 
ultrasound exposure. Note that in all the experiments with doxorubicin-containing samples an extra 
centrifugation step (5 min at 1100 rpm) was performed 15 min after ultrasound exposure, to remove 
any excess of free doxorubicin or doxorubicin-liposomes after treatment. After this centrifugation step 
all samples were heated for 15 min at 42°C, and subsequently left to incubate for 24h before analysis. 
In all microscopy experiments, Hoechst 33342 (Thermo Fisher Scientific, Waltham, WA, USA) was 




Figure 2: Ultrasound treatment of spheroids. (A) Schematic representation of the experimental set-up. Spheroids and 
microbubbles/liposomes were brought into ultrasound-transparent Lumox dishes, which were submerged in a water bath 
containing a rubber bottom layer and subsequently exposed to ultrasound radiations. (B) Schematic representation of the 
ultrasound treatment. 1 MHz ultrasound was applied for 10 s, at 2W/cm², corresponding to approx. 700 kPa, with 10% duty 
cycle and 2000 cycles (i.e. 2 ms) per pulse. 
Flow cytometry  
To analyze the delivery of liposomes to the spheroids, spheroids were first dissociated into a single cell 
suspension. Therefore, the spheroids were incubated with 1 mL of Trypsin - EDTA (0.25%, Gibco™) for 
5 min, whereafter they were further disintegrated into single cells mechanically  using a 21G needle 
(BD, Franklin Lakes, NJ, USA) attached to a 1 mL syringe (BD). Afterwards, the trypsin was neutralized 
by fresh culture medium and the single cell suspensions were finally resuspended in flow buffer (i.e. 
PBS-/- (Gibco™) supplemented with 1% of BSA (Sigma Aldrich) and 0.5% of NaN3 (Sigma Aldrich). Flow 
cytometry data were acquired using a CytoFLEX (Beckman Coulter Life Sciences, Indianapolis, IN, USA) 
and analyzed using FlowJo™ software. During analysis, compensation for spectral overlap was 
performed and single cells were gated to remove the signals from remaining cell doublets and triplets. 
The loading capacity of microbubbles with fluorescently-labeled liposomes was evaluated with flow 
cytometry as well. To this end, the liposomes were added to the microbubbles in the specified ratios 
(10; 20; 50 µL liposomes to 1 mL of microbubbles) and left to incubate for 5 min before analysis by 
flow cytometry. As before, flow cytometry data of microbubbles were acquired using a CytoFLEX and 
analyzed using FlowJo™ software. Gating was performed to selectively measure the microbubble-
bound liposomal fluorescence.  
Confocal microscopy 
All confocal microscopy images were recorded on a C1-si confocal microscope (Nikon, Amsterdam, The 
Netherlands) equipped with a 60× water immersion objective (NIR Apo, Nikon) and a 10x air objective 
(Plan Apo, Nikon). A 405 nm laser was used to visualize Hoechst 33342/DAPI associated with the 
cellular nuclei; a 488 nm laser was used to excite fluorescent doxorubicin, while the emitted signal was 
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detected over the TRITC emission window. Finally, a 637 nm laser was used to visualize DiD, present in 
the liposomal bilayer. Confocal imaging was performed on 10 µm thick cryosections, as well as on 
intact spheroids. Living spheroids were transferred to glass-bottom microscopy grade dishes 
(CELLview™ cell culture dishes, Greiner Bio-One, Kremsmünster, Austria) for imaging. Optical cross-
sections of the spheroids were acquired using the 60x objective with a 1 µm increment to produce Z-
stacks of the entire spheroid volume. To determine the radial fluorescence plot profile in a single cross-
section, the ‘Radial Profile’ plug-in for the image analysis software ImageJ (NIH, MD, USA) was used. 
Histology  
Paraffin-embedded sections 
The spheroids were fixated in 4% paraformaldehyde (PFA) (VWR, Radnor, PA, USA), dehydrated 
through an ethanol concentration gradient and embedded in paraffin. Sections of 5 µm thickness were 
cut (Cut4060; Slee Medical, Mainz, Germany) and deparaffinized. Histological staining was done using 
a standard protocol for hematoxylin-eosin to evaluate cell morphology. The presence of extracellular 
matrix in the spheroids was tested by collagen I staining (1:150, R1086, Acris Antibodies GmbH, 
Herford, Germany). In short, the sections were enzymatically digested by incubation with 1 mg/mL 
pepsin at 37°C for 30 min, followed by 2h of incubation with a monoclonal mouse anti-collagen I 
antibody after pretreatment with 3% H2O2 for 10 min and blocking with BSA and 4% normal rabbit 
serum in PBS. Afterwards streptavidin-peroxidase was added for 30 min before a secondary antibody 
(biotinylated swine anti rabbit, 1:200, E2431, Dako, Agilent Technologies, Santa Clara, CA, USA) was 
introduced. Finally, the sections were incubated with DAB for 10 min and counterstained with 
hematoxylin. Imaging was subsequently performed on an Olympus BX51 microscope. 
Cryosections 
Spheroids were fixated in 4% PFA for 30 min prior to embedding in Tissue-Tek® O.C.T. (Sakura Finetek 
USA Inc, Torrance, CA, USA). The spheroids were subsequently snap-frozen with liquid nitrogen and 10 
µm sections were prepared using a Cryotome® FSE (Thermo Fisher Scientific, Cheshire, UK) and 
allowed to adhere to Superfrost microscopic glass slides (Menzel-Gläser, Braunschweig, Germany). The 
sections were air dried for 20 min before adding DAPI-containing mounting medium. The cryosections 
were visualized under confocal microscopy as described before. 
Cell viability assays 
To estimate the spheroid viability after treatment, an ATP-based CellTiter-Glo® 3D Cell Viability Assay 
(Promega Corporation, Madison, WI, USA) that is optimally adapted for the evaluation of toxicity in 3D 
cell cultures43, was performed. For this, the spheroids were transferred to low adherent gyratory 
shaker flasks after treatment and placed on a shaker plate at 37°C and 70 rpm, to remain in 3D culture 
until analysis. After 72h, the spheroids were incubated with the CellTiter-Glo® 3D reagent and analyzed 
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as described by the manufacturer, using a GloMax® 96 Microplate luminometer (Promega). Cell 
viability was normalized against untreated spheroids. 
To selectively evaluate the viability of tumor cells within the mono- and cocultures, a firefly luciferase 
assay was performed on spheroids containing Luciferase positive 4T1 cells. As for the CellTiter-Glo® 
assay, the spheroids were kept in 3D cultures after treatment by gyratory shaking for 72h. Afterwards, 
the spheroids were incubated with a 5x dilution of Luciferase Cell Culture Lysis 5X Reagent (Promega) 
for 20 min. The resulting solution was transferred to a white flat-bottom 96-well plate (Corning 
Incorporated, Corning, NY, USA) and the 4T1-derived luciferase activity was determined using the 
Luciferase Assay System from Promega. A CLARIOstar luminometer (BMG Labtech, Cary, NC, USA) with 
injection system was programmed to perform a 2s delay, follow by a 10s read-out, as instructed by the 
manufacturer. 
Incucyte® live cell analysis  
Spheroid morphology was evaluated using the IncuCyte® ZOOM System ((Essen Bioscience, 
Hertfordshire, UK) over 72h. For this, a single spheroid was handpicked under a light microscope (Wild 
Heerbrugg, Heerbrugg, Switzerland) and transferred to a Corning® 96-well Clear Round Bottom Ultra-
Low Attachment Microplate (Corning Incorporated, Corning, NY, USA) containing 100 µL full medium. 
The plate was inserted in the Incucyte ZOOM System and images at 10x magnification were taken every 
1,5 to 2h for 72h.  
Statistical analysis 
All experiments were performed independently on different days with a minimum of 3 biological 
replicates. Statistical analysis was performed using one-way ANOVA analysis with a Bonferroni’s 
multiple comparison test, as calculated by GraphPad Prism 6 (GraphPad software, San Diego, CA, USA) 
and expressed as the mean ± standard deviation. 
Results 
Generation of mono- and cospheroids 
Spheroids were generated using an 400 µm agarose-based microwell array platform, as developed by 
Vrij et al37, in which single cells assemble into multicellular spheroid cultures of approximately 100 to 
150 µm in size within 48h (figure 3A). Based on earlier work by Priwitaningrum et al.7 we prepared 4T1 
breast cancer monospheroids and cospheroids consisting of 4T1 breast cancer cells and NIH/3T3 
fibroblasts in a 1:5 ratio. The addition of fibroblasts yields a more biologically relevant model due to 





Figure 3: Mono- and cospheroids. (A) Bright-field image of cospheroids grown in microwells (grey circles) after 48h. The scale 
bar represents 200 µm. (B&C) Confocal images of (B) a monospheroid consisting of only 4T1 tumor cells, labeled with 
CellTrace™ Yellow, and (C) a cospheroid consisting of 4T1 tumor cells and NIH/3T3 fibroblasts in a 1:5 ratio, differentially 
labeled with CellTrace™ Yellow and CellTrace™ Blue, respectively, 48h after seeding (cross-section at 25-30 µm from the top). 
The scale bar represents 50 µm. (D&E) Collagen-1 staining (brown) on paraffin sections (cells in violet) of (D) monospheroids 
showing little to no collagen formation and (E) cospheroids indicating the presence of an extracellular matrix. The scale bar 
represents 50 µm. 
To characterize the cellular organization of the spheroids, NIH/3T3 and 4T1 cells were labeled with two 
different CellTrace™ dyes prior to spheroid formation and the spheroids were subsequently imaged by 
confocal microscopy, as shown in figure 3B&C. Figure 3B and C show the localization of 4T1 cells 
(yellow) and NIH/3T3 cells (blue) in mono- and cospheroids respectively. Due to differences in cellular 
density and in intercellular adhesiveness, the  fibroblasts tend to cluster among themselves and to 
accumulate within the center and on the outer part of the spheroids36,44. To confirm that the fibroblasts 
formed an extracellular matrix, we investigated the presence of collagen-1 in both mono- and 
cospheroids, as seen in figure 3D and 3E. While collagen-1 (brown color) is abundantly present in the 
cospheroids (figure 3E), almost no collagen-1 could be found in the monospheroids (figure 3D). 
Additionally, the collagen-1 is predominantly found in the center of the cospheroids which is in 
accordance with the confocal images showing that a high concentration of fibroblasts was found in 
this area. 
Sonoprinting of model nanoparticles on tumor spheroids 
In previous work, we  showed that the ultrasound-triggered delivery of nanoparticles to cells growing 
in 2D monolayers was significantly enhanced when the nanoparticles were loaded onto the 
microbubble shell; we termed this phenomenon sonoprinting (figure 1)25. To determine if sonoprinting 
also occurs on free-floating 3D spheroids, and in the absence of ultrasound-reflecting membranes, we 
loaded two types of nanoparticles onto microbubbles using a biotin-avidin-biotin link. Figure 4 shows 
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confocal microscopy images of fluorescent polystyrene bead-loaded (figure 4A) and DiD-labeled 
liposome-loaded microbubbles (figure 4B) and their size distribution, as determined by Coulter 
Counter (figure 4C). The size of the microbubbles ranged from 1 to 10 µm, with an average size of 2.5 
µm for unloaded microbubbles and 2.6 µm and 2.8 µm for liposome-loaded and bead-loaded 
microbubbles, respectively. The size and polydispersity index (pdI) of the different nanoparticles used 
in this study are summarized in supplementary table 1.  
 
Figure 4. Characterization of nanoparticle-loaded microbubbles. (A-B) Confocal image of microbubbles loaded with (A) 
yellow-green fluorescent 100 nm polystyrene beads (green) and (B) DiD-labeled liposomes (LIP) (red). The scale bars 
represent 5 µm. (C) Size distribution of unloaded (black), polystyrene bead-loaded (green) and liposome-loaded (red) 
microbubbles, as determined via Coulter Counter. 
First, biotinylated fluorescent polystyrene beads were used as model nanoparticles as they are inert 
and do not leak the entrapped dye. Flow cytometry analysis of the spheroid-derived cells 4h after 
treatment revealed that loading the beads on the microbubbles significantly improved their delivery 
to the spheroid-derived cells, when compared to the beads-only sample and the coadministration 
sample (figure 5B, black bars). These results collectively confirm that sonoprinting cannot only occur 
in 2D cell cultures but also on free-floating 3D tumor spheroids. An almost identical result was obtained 
in the case of cospheroids (figure 5C, black bars) which suggests that the tumor stroma has no impact 
on the sonoprinting process.  
The same experiments were repeated with fluorescently (DiD) labeled liposomes, which are highly 
versatile  drug carriers able to encapsulate both low molecular weights drugs (chemotherapeutics, 
corticosteroids) and complex biological therapeutic agents (mRNA, siRNA)2,45–47. As presented in figure 
5B and C (grey bars), the delivery of liposomes to the cells of the mono- and cospheroids clearly 





Figure 5: Sonoprinting of polystyrene beads and liposomes on tumor spheroids. (A) Time diagram: 4h after ultrasound 
treatment, the spheroids were analyzed by flow cytometry. (B-C) Normalized (to blank) mean intensity fluorescence (MFI; as 
determined by flow cytometry) of spheroid-derived cells from (B) monospheroids and (C) cospheroids. NP = nanoparticles; 
MB = microbubbles; US = ultrasound; NP + MB + US = nanoparticles and microbubbles coadministered and exposed to 
ultrasound radiation; NP-MB + US = nanoparticles loaded onto the microbubbles and exposed to ultrasound (i.e. 
sonoprinting). Significance levels are determined using a Bonferroni multiple comparison test: *** represents P<0.001. 
However, since single cell suspensions are required for flow cytometric analysis, the results in figure 5 
do not reveal where in the 3D spheroids the polystyrene beads or liposomes were delivered.  
Consequently, we further investigated the location of the fluorescent liposomes within the tumor 
monospheroids by confocal microscopy, as shown in figure 6. To this end, individual cross-sections (as 
illustrated in figure 6H) over the entire depth of the spheroid were made with a 1 µm increment, from 
which the entire spheroid could be reconstructed (as illustrated in figure 6G). In correspondence with 
the flow cytometry results (figure 5), the reconstructed volume views of the spheroids in figures 6B-E 
indicate that loading of the liposomes on the microbubbles and subsequent ultrasound treatment 
significantly enhanced  the delivery of liposomes to the tumor spheroids (figure 6E). This is in sharp 
contrast to spheroids that were treated with liposomes alone (figure 6C) and coadministered 
liposomes and microbubbles (figure 6D). The individual cross-sections at increasing depth of the 
spheroid treated with liposome-loaded microbubbles and ultrasound are shown in figure 6F and 
revealed that liposome penetration is restricted to the outer layers of the tumor spheroid. As the 
tumor spheroids  were on average 150 µm in size and light penetration is typically limited to a few tens 
of microns36,48,49, it  was impossible to visualize the inner part of the tumor spheroids by confocal 
microscopy. This is also clear from the radial fluorescence profile plot (figure 6I), derived from the 
cross-section at 40 µm in figure 6F. The plot illustrates that the nuclear staining (blue line, figure 6I) 
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could be retrieved in deeper layers of the tumor spheroid compared to the fluorescent liposome signal 
(red line), despite the fact that the 637 nm laser light used to excite the liposomes has a better tissue 
penetration than the 405 nm laser light used to excite the Hoechst nuclear stain50. These results 
confirm that the loss in liposomal signal at deeper locations in the spheroids is not due to a loss in 
fluorescence, though attributed to the fact that the liposomes are indeed printed superficially on the 
tumor spheroid. Together, these results indicate that liposomes can be sonoprinted on free-floating 
3D tumor spheroids, yet the delivery remains restricted to the outer cell layers of the spheroids.  
 
Figure 6: Sonoprinting on 4T1 tumor monospheroids. Blue = Hoechst 33342 nuclear stain, red = liposomes (DiD). (A) Time 
diagram: 4h after ultrasound treatment, the spheroids were analyzed by confocal microscopy. (B-D) Maximum intensity 
projections of confocal Z stacks taken from (B) an untreated spheroid, (C) a spheroid exposed to DiD-labeled liposomes only, 
(D) a spheroid exposed to DiD-labeled liposomes and microbubbles coadministered and exposed to ultrasound and (E) a 
spheroid exposed to DiD-labeled liposomes coupled onto microbubbles and exposed to ultrasound (i.e. sonoprinting). The 
dimensions of the white boxes are: 212 µm x 212 µm x 90 µm. (F) Individual cross sections of the spheroid in (E) at increasing 
depth. The center of the spheroid cannot be visualized by confocal microscopy due to limited light penetration. The scale 
bars represent 50 µm. (G) The maximum intensity projection of the spheroid is composed from stacks of cross sections in the 
z direction. (H) The radial profile plot is created by measuring the fluorescence profile over radius r over the entire spheroid. 
(I) Radial profile plot of the nuclear stain (blue) and the liposomal stain (red) from the spheroid center (0 µm) to the edges.  
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Doxorubicin release from sonoprinted DOX-liposomes  
To investigate delivery of drugs subsequent to sonoprinting, we included the chemotherapeutic 
doxorubicin (DOX) in the liposomes. Doxorubicin is a small drug that can easily cross cell and nuclear 
membranes to reach the nucleus where it intercalates in DNA to exert its cytotoxic function. First, we 
estimated the amount of doxorubicin per liposome to be 3,1 x 10-10 µg doxorubicin/liposome on 
average, which is comparable to the doxorubicin content of clinically approved Doxil®51. The active 
loading of doxorubicin into the liposomes increased their size to approximately 200 nm 
(supplementary table 1). In these experiments, spheroids were treated with either free doxorubicin, 
DOX-liposomes only or DOX-liposomes either coadministered with or coupled onto microbubbles. In 
all samples, the doxorubicin concentration was kept identical. In case DOX-liposomes were coupled 
onto the microbubbles, we calculated that 1,6 x 10-7 µg doxorubicin was loaded onto each 
microbubble, based on the microbubble concentration (1,118 x 109 per mL) and the concentration of 
unbound liposomes in the solution (4 x 1011 per mL, corresponding to approx. 45% of the total amount 
liposomes in the solution), as outlined in materials and methods.  
As doxorubicin is a fluorescent molecule, both the drug-derived fluorescence and the liposome-derived 
fluorescence on the spheroid-derived cells could be individually measured by confocal imaging and 
flow cytometry (figure 7). The scatter plot presented in figure 7B, clearly indicates that more liposomes 
(y-axis) and doxorubicin (x-axis) were delivered to the monospheroid-derived cells 24h after 
treatment, only when exposed to DOX-liposome-loaded microbubbles and ultrasound (dark green 
dots). This population still exhibits a clear gradient in fluorescence, suggesting that the position of the 
cell within the spheroid strongly influenced to which extent liposomes/doxorubicin were taken up. This 
corresponds to the data in figure 6 where cells located in the outer layers of the spheroids showed a 
higher uptake of fluorescent liposomes. We also noticed a strong correlation between the liposomal 
and doxorubicin fluorescence, which suggests that intact DOX-liposomes were printed on the tumor 
spheroids and still contained the doxorubicin 24h after being printed. As expected, free doxorubicin 
(dark blue dots) penetrates the tumor spheroids very well, while the coadministration sample (light 
green dots) and liposome-only sample (orange dots) overlap and only show a modest increase in both 
liposomal and doxorubicin fluorescence. The corresponding histograms can be found in supplementary 
figure 1A,C,E,G and confirm that the treatment with DOX-liposome-loaded microbubbles and 
ultrasound resulted in an increased delivery of liposomal DiD and doxorubicin to the spheroid cells, 
even though differences in doxorubicin delivery are more difficult to distinguish due to the relatively 
low fluorescence of doxorubicin, which is moreover quenched by incorporation into liposomes52. While 
the overall shifts in MFI were less, a similar trend was found in cospheroids (figure 7C and 
supplementary figure 1E,G).  
16 
 
Doxil®  liposomes are known to be highly stable towards drug leakage, for up to 2 weeks in vitro42,51,53,54. 
As the regular DOX-liposomes have a similar composition to Doxil®, it is difficult to experimentally 
verify whether doxorubicin can leak from the regular DOX-liposomal prints and penetrate into the 
deeper-lying tissue. Therefore, we prepared a thermosensitive DOX-liposomal formulation resembling 
ThermoDOX®, which is currently in phase III clinical trials41. These liposomes contain the lysolipid 
MSPC, which enables the disintegration of the liposomal structure upon heating to 42°C (i.e. the Tm of 
MSPC) and, consequently, the release of encapsulated doxorubicin. Tumor spheroids were treated 
with the same samples as in Figure 7B&C, though instead of regular DOX-liposomes, thermosensitive 
DOX-liposomes were used. Due to the heating (15 min at 42°C), doxorubicin was able to leak out of 
the thermosensitive DOX-liposomes. The scatter plots of monospheroids (figure 7F) and cospheroids 
(figure 7G) exposed to thermosensitive DOX-liposome-loaded microbubbles and ultrasound revealed 
that part of the doxorubicin was indeed able to leak out of the liposomal prints, as the correlation 
between liposomal and DOX fluorescence became less prominent (dark green dots). Moreover, as the 
doxorubicin fluorescence is no longer quenched, an enhancement in the fluorescence signal can be 
seen after doxorubicin was released from the thermosensitive liposomes. Furthermore, cells derived 
from tumor spheroids treated with free DOX-liposomes (orange dots) or the coadministration sample 
(light green dots) also showed a higher fluorescence intensity of doxorubicin and liposomal DiD (figure 
7F&G and supplementary figure 1B,D,F,H). This could possibly be due to a release of the lipophilic DiD 
dye from liposomal fragments that remain after washing and a dequenched fluorescence of the 
released doxorubicin in these samples. Still, coupling thermosensitive DOX-liposomes onto 
microbubbles significantly improved the delivery. Again, a trend toward lower delivery in the 
cospheroids was seen when comparing the histograms of monospheroids to cospheroids 
(supplementary figure 1B,D,F,H). 
To confirm these results and get a better view on the  localization of the liposomes and the doxorubicin 
within the tumor spheroids, we made cryosections of the tumor spheroids 24h after ultrasound 
treatment, and imaged them with confocal microscopy (figure 7D,E,H,I and supplementary figure 2). 
The localization of liposomes (red fluorescence) and doxorubicin (orange fluorescence) within the 
spheroids was investigated after sonoprinting of both regular (figure 7D-E) and thermosensitive (figure 
7H-I) DOX-liposomes. The individual fluorescence channels can be found in supplementary figure 3. 
For regular DOX-liposomes, the liposomal signal clearly overlaps with the doxorubicin fluorescence and 
both signals are limited to the outer layers of the spheroids (figure 7D-E), as was expected considering 
the slow doxorubicin release from such liposomes42,51,53,54. In contrast, the cryosections of spheroids 
sonoprinted with the thermosensitive formulation (figure 7H-I) confirmed that, following a short 
heating, doxorubicin was able to leak out of the liposomes and penetrate further into the tumor 
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spheroid. Contrarily to what has been reported before55,56, the presence of the stroma in the 
cospheroids did not hamper the doxorubicin penetration in the cospheroids  (figure 7I), indicating that, 
once release from the liposomes, doxorubicin is able to easily penetrate this stromal barrier. The 
cryosections from both mono- and cospheroids treated with DOX-liposomes only or DOX-liposomes 
coadministered with microbubbles and exposed to ultrasound, only showed limited doxorubicin 
fluorescence within the tumor spheroids (supplementary figure 2). Again, a minor increase in 
doxorubicin fluorescence in the spheroid cells treated with the thermosensitive DOX-liposome samples 





Figure 7: Localization of doxorubicin after sonoprinting and a short heating step. (A) Time diagram: 15 min after ultrasound 
treatment, the spheroids were centrifuged to remove any remaining free doxorubicin or DOX-liposomes. Subsequently, the 
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spheroids were exposed to 42°C for 15 min. After 24h, the spheroids were analyzed by flow cytometry and confocal 
microscopy on cryosections. (B,C,F,G) Flow intensity scatter plots of the cellular delivery of doxorubicin (doxorubicin 
fluorescence, horizontal axis) and (B-C) regular and (F-G) thermosensitive liposomes (DiD fluorescence, vertical axis) in (B&F) 
monospheroids and (C&G) cospheroids. DOX = doxorubicin; LIP = DOX-liposomes; MB = microbubbles; US = ultrasound; LIP + 
MB + US = DOX-liposomes and microbubbles coadministered before ultrasound radiation; LIP-MB + US = DOX-liposomes 
loaded onto the microbubbles and exposed to ultrasound (i.e. sonoprinting). (D,E,H,I) 10 µm cryosections of (D&H) 
monospheroids and (E&I) cospheroids treated with (D-E) regular or (H-I) thermosensitive DOX-liposomes coupled onto 
microbubbles and exposed to ultrasound. Blue = DAPI, orange = doxorubicin, red = liposomes (DiD). The scale bars indicate 
50 µm. 
Cytotoxicity of sonoprinted DOX-liposomes  
To evaluate the cytotoxic effect of the printed DOX-liposomes, morphological changes in mono- and 
cospheroid were monitored during 72h after treatment with DOX-liposome-loaded microbubbles and 
ultrasound. Figure 8B&D show that untreated mono- and cospheroids grew similarly in size over time. 
In contrast, clear morphological differences between monospheroids and cospheroids treated with 
DOX-liposome-loaded microbubbles and ultrasound were seen (figure 8C&E): while monospheroids 
desintegrated (figure 8C), cospheroids mainly shed cell fragments (figure 8E). Highly likely, this can be 





Figure 8: Spheroids monitored over 72h after treatment. (A) Time diagram: 15 min after ultrasound treatment, the spheroids 
were centrifuged to remove any remaining free doxorubicin or DOX-liposomes. Subsequently, the spheroids were exposed 
to 42°C for 15 min. Afterwards, the spheroid morphology was followed over a period of 72h. Phase contrast images of (B) 
untreated monospheroids and (C) monospheroids treated with regular DOX-liposomes coupled onto microbubbles and 
exposed to ultrasound (LIP-MB + US). (D) Untreated cospheroids and (E) cospheroids treated with regular liposomes coupled 
onto microbubbles and exposed to ultrasound (LIP-MB + US). The scale bars indicate 50 µm. 
Based on these images, it is clear that it is more convenient to analyze cell toxicity at a later time-point, 
, as is expected from the fact that doxorubicin works by inhibiting DNA synthesis and will therefore 
only be effective on dividing cells. Therefore, we subsequently assessed the total cell viability of the 
tumor spheroids 72h after treatment, using a CellTiter-Glo® 3D Cell Viability Assay. Figure 9 shows the 




Figure 9: Total cell viability of tumor spheroids 72h after treatment. (A) Time diagram: 15 min after ultrasound treatment, 
the spheroids were centrifuged to remove any remaining free doxorubicin or DOX-liposomes. Subsequently, the spheroids 
were exposed to 42°C for 15 min. After 72h, the spheroids were analyzed using a CellTiter-Glo® 3D Viability Assay. (B) Cell 
viability after treatment of (A) monospheroids and (B) cospheroids. DOX = doxorubicin; LIP = DOX-liposomes; MB = 
microbubbles; US = ultrasound; LIP + MB + US = DOX-liposomes and microbubbles coadministered before ultrasound 
radiation; LIP-MB + US = DOX-liposomes loaded onto the microbubbles and exposed to ultrasound (i.e. sonoprinting). 
Significance levels are determined using a Bonferroni multiple comparison test: ns for P>0.05, * for P<0.05, ** for P<0.01, 
*** for P<0.001. 
Sonoprinting of DOX-liposome-loaded microbubbles resulted in a significantly cytotoxicity compared 
to the liposomes alone and the liposomes coadministered with microbubbles and exposed to 
ultrasound, and was equally effective as free doxorubicin. Moreover, in contrast to the control samples 
where the thermosensitive DOX-liposomes (grey bars) appeared more toxic than the regular liposome 
samples (blue bars), this effect was observed for both regular and thermosensitive DOX-liposomes 
when coupled onto microbubbles and exposed to ultrasound. This suggests that doxorubicin must 
have been able to leak from the regular DOX-liposomes at a later time point as free doxorubicin was 
not yet detected in the cryosections 24h after treatment (figure 7). To confirm this, additional 
cryosections of monospheroids were made at different time points after treatment with DOX-
liposome-loaded microbubbles and ultrasound and imaged by confocal microscopy (figure 10). 
Doxorubicin leakage from the thermosensitive liposomal patches occurred within 4h (figure 10B) while 
DOX release from the regular liposomes only started 48h after sonoprinting (figure 10C), confirming 




Figure 10: Doxorubicin release from sonoprinted liposomal patches. (A) Time diagram: 15 min after ultrasound treatment, 
the spheroids were centrifuged to remove any remaining free doxorubicin or DOX-liposomes. Subsequently, the spheroids 
were exposed to 42°C for 15 min. After (B) 4h for thermosensitive DOX-liposomes or (C) 48h for regular DOX-liposomes, the 
spheroids were analyzed by confocal microscopy on cryosections. Orange = doxorubicin, red = liposomes (DiD). The scale bars 
indicate 50 µm. 
The presence of fibroblasts in cancerous tissues can have a pro-carcinogenic effect, partly due to the 
formation of a dense extracellular matrix that acts as a physical transport barrier for drugs, thereby 
rendering anti-cancer treatments less efficient8,31,34,57. Therefore, the protective effect of the NIH/3T3-
derived matrix on the 4T1 tumor cell viability was evaluated using an additional toxicity test. In this 
assay we included 4T1 cells that were stably transfected with luciferase. By measuring the luciferase 
expression we were able to selectively evaluate the viability of 4T1 tumor cells in mono- and 
cospheroids, 72h after treatment (figure 11). The results obtained on spheroids treated with DOX-
liposomes alone and DOX-liposomes coadministered with microbubbles and exposed to ultrasound 
indicate that 4T1 cells in the cospheroids were less efficiently killed. This confirms that NIH/3T3 
fibroblasts can indeed protect the tumor cells from doxorubicin. However, upon treating the spheroids 
with both types of DOX-liposome-loaded microbubbles and ultrasound, the treatment was equally 
effective in killing the tumor cells in mono- and cospheroids. Similar to the results in figure 9, the DOX-
liposome-loaded microbubbles resulted in an overall stronger reduction of tumor cell viability than the 




Figure 11: Selective viability of 4T1 tumor cells 72h after treatment. (A) Time diagram: 15 min after ultrasound treatment, 
the spheroids were centrifuged to remove any remaining free doxorubicin or DOX-liposomes. Subsequently, the spheroids 
were exposed to 42°C for 15 min. After 72h, the viability of the luciferase positive tumor cells was analyzed using a Luciferase-
based viability assay. Tumor cell viability after treatment with (B) regular DOX-liposome samples and (C) thermosensitive 
DOX-liposome samples. DOX = doxorubicin; LIP = DOX-liposomes; MB = microbubbles; US = ultrasound; LIP + MB + US = DOX-
liposomes and microbubbles coadministered before ultrasound radiation; LIP-MB + US = DOX-liposomes loaded onto the 
microbubbles and exposed to ultrasound, i.e. sonoprinting. Significance levels are determined using a Bonferroni multiple 





In this study, we found that treatment of free-floating spheroids with nanoparticle-loaded 
microbubbles and ultrasound results in the superficial deposition of the nanoparticles on the spheroid 
surface (figure 5&6). The patches closely resemble the sonoprinted patches that we observed before 
in 2D cell cultures25. Both inert polystyrene beads (which cannot leak any fluorophore) and liposomes 
could be sonoprinted onto the tumor spheroids, as seen in figure 5, indicating that the liposomes 
remained intact and that the treatment did not result in liposomal fragmentation or leaching of the 
liposomal dye. This is supported by the findings of Luan et al.58, who showed that intact liposomes are 
released from the microbubble shell upon microbubble cavitation. 
Our results furthermore show that nanoparticle delivery is limited to the outer cell layers of the 
spheroids (figure 6), which can be explained by the fact that sonoprinting occurs following a direct 
interaction between nanoparticle-loaded microbubbles and cells, as schematically presented in figure 
1)26. In addition, the fact that the deposition of the nanoparticles remains restricted to the surface of 
the spheroids is supported by earlier findings that show limited penetration of liposomes in tissues 
(maximally 40-50 µm from the nearest blood vessel), depending on their size and charge7,59–62. 
Moreover, we have previously shown that upon release from the microbubbles, the nanoparticles 
remain (party) attached to fragments of the microbubble shell26, possibly leading to clusters of 
nanoparticles that might contribute to the restricted penetration as well.  
Although nanoparticle penetration in the spheroids remained restricted, we observed that the 
nanoparticle patches can serve as a local reservoir from where drugs can be released and, finally, reach 
deeper lying cells (figure 7). Since the regular DOX-liposomes showed little doxorubicin leakage after 
24h (figure 7D&E), we employed thermosensitive liposomes to induce rapid doxorubicin release (figure 
7H&I). In this way, we confirmed that doxorubicin released from sonoprinted liposomal patches was 
able to penetrate deeper into the tissue to eventually reach the nuclei of cells all the way to the center 
of the spheroid.  
It seems counterintuitive that a comparable cytotoxicity was achieved when spheroids were treated 
with microbubbles carrying either regular DOX-liposomes or thermosensitive DOX-liposomes (figure 9 
and 11). Especially as doxorubicin remained encapsulated in the regular DOX-liposomes (at least at 
24h after treatment) while it was immediately released from the thermosensitive DOX-liposomes upon 
short heating (figure 7). However, both the spheroid morphology (figure 8) and the doxorubicin 
leakage after 48h (figure 10) suggest that  the cytotoxic effects  by regular DOX-liposomes  occur at a 
later time compared to thermosensitive DOX-liposomes, indicating that doxorubicin was eventually 
able to leak out of regular DOX-liposomes and lead to equal cell killing after 72h. The mechanisms 
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which govern release of doxorubicin from Doxil® (being comparable to the regular DOX-liposomes in 
this study) are not yet fully elucidated51,63,64. Doxil® liposomes have been reported to leak doxorubicin 
extremely slowly in vitro42,53, which does not seem to explain their effect in vivo.  Regarding the release 
in vivo, it has been suggested that the uptake of Doxil® liposomes by a selected population of tumor 
cells and/or macrophages might result in apoptosis of these cells and a subsequent release of the 
remaining free doxorubicin present in their cytosol42,53,63. Another hypothesis is that, since doxorubicin 
is encapsulated in the liposomes through remote loading in the presence of ammonium sulfate or 
similar, an enhanced ammonia concentration at the tumor site (through an activation of the 
glutaminolysis pathway) may reverse the encapsulation process and result in a rapid release of the 
doxorubicin51. Whether or not these mechanisms play a role in tumor spheroids in this study, remains 
an open question.  
Even though mono- and cospheroids vary significantly in composition, only minor differences in 
penetration of liposomes and doxorubicin were found (figure 7 and supplementary figure 1). Since 
DOX-liposomes were not able to infiltrate monospheroids, it comes as no surprise that they were 
unable to infiltrate cospheroids either, as inclusion of fibroblasts makes the penetration barrier even 
stronger7,34,65. However, free doxorubicin easily penetrated both mono- and cospheroids, in contrast 
to earlier reports, where limited penetration of doxorubicin in spheroids with high stromal content 
was observed55,56. Possibly the rather small size of the spheroids used in this study, allowed doxorubicin 
to penetrate throughout the entire spheroid volume, regardless of the stromal content. Also, larger 
spheroids can develop an acidic core, due to insufficient removal of waste products. This lower pH can 
protect the cells from weak acid drugs such as mitoxantrone and anthracyclines32, an effect that is 
most likely not present in  the tumor spheroids used in this study. Nevertheless, the selective toxicity 
assay (figure 11) revealed the pro-carcinogenic effect of cancer-associated fibroblasts in our spheroids, 
as DOX-liposomes alone and DOX-liposomes coadministered with microbubbles and exposed to 
ultrasound were more effective in mono- than in cospheroids. Yet, loading DOX-liposomes onto 
microbubbles resulted in a stronger killing of the 4T1 tumor cells in both mono- and cospheroids.  
While tumor spheroids have a higher cellular complexity than monolayer cultures and are therefore a 
better representative of the in vivo situation, there are evidently some limitations to their predictability 
as well. Since microbubbles are too large to extravasate, they will remain inside the vascular 
compartment in vivo. As a result, the presence of both blood flow and an endothelial cell layer would 
normally permit only a brief and indirect contact between the target tissue and the drug-carrying 
microbubbles. However, when using targeted microbubbles, it is possible to locally induce 
accumulation of the microbubbles and extend the contact time, to resemble the conditions present in 
this study. Targeting can be achieved through the incorporation of tumor vasculature-specific ligands, 
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like cyclic RGD or E-selectin, on the microbubble shell66–68, as well as through physical forces such as 
the application of an external magnetic field69,70 or ultrasound-induced radiation forces71–73. Adding 
targeting moieties to the liposomes could also affect the liposomal uptake through receptor-mediated 
internalization74. Secondly, the lack of an endothelial cell layer in this spheroid model makes it 
impossible to evaluate the impact of this barrier in the current study. Nevertheless, it has been 
extensively shown that ultrasound-driven microbubbles can lead to the disruption of the vascular wall 
through the formation of pores in the endothelial cell membranes and the opening of gap 
junctions,62,75,76 as notably exemplified for the highly impermeable vascular wall that makes up the 
blood-brain-barrier77,78. However, unlike in brain parenchyma, where any cell is within 2 or 3 cells away 
from a blood vessel77, peripheral tumors can form avascular regions where viable cells can be as far as 
200 µm away from the nearest capillaries79,80. An efficient treatment of such tissues requires a therapy 
that can overcome the enhanced stromal barrier and can reach the deeper laying layers. Therefore, 
3D multicellular models remain suitable models for in vitro evaluation of tumor treatment strategies.  
Future studies could be performed on more advanced 3D cultures, to obtain a better understanding 
and predictability of ultrasound-mediated therapeutic applications. For example, tumor spheroids 
encompassing blood vessel-like structures can provide a better representation of the vascular barrier 
81,82. Alternatively, tumor spheroids grown in microfluidic chips could be employed as they mimic the 
blood flow around the tissue more accurately83,84. However, it is important to remember that confined 
spaces and rigid membranes yield acoustic artefacts, limiting the use of chip-based culture systems for 
the evaluation of ultrasound-mediated therapeutic applications. 
While this study focused on understanding the mechanisms of sonoprinting in soft tissues, we envision 
that apart from the delivery of chemotherapeutics with a poor risk-benefit ratio, sonoprinting might 
be beneficial to several localized therapies in vivo. Due to the superficial nature of the observed effects, 
it can be expected that only targets within and directly around the bloodstream can be reached. 
However this opens up possibilities for those applications that can benefit from endothelial drug 
delivery. Examples in this context are the local treatment of bacterial biofilms and atherosclerotic 
plaques. In earlier work we have demonstrated that sonoprinting using microbubbles loaded with 
genetic drugs (pDNA, mRNA) can also result in high gene expression levels40,85, which could be useful 
to alter the tumor microenvironment by means of  cancer immunotherapy. To allow the in vivo 
translation of sonoprinting for tumor therapy, the microbubble loading capacity needs to be sufficient 
to achieve the desired drug dose. A single injection of Doxil® liposomes is administered to patients in 
a concentration ranging from 20-50 mg doxorubicin/m², depending on the indication. This corresponds 
to 34-85 mg doxorubicin for a regular adult patient. Since we calculated that on average 1.6 x 10-7µg 
doxorubicin is loaded onto one microbubble, approx. 1011 of these microbubbles should be 
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administered to the patient to attain a similar drug dose. The recommended dose of the clinically 
approved contrast agent Definity® equals 1010 microbubbles for a regular adult patient24. However, it 
has been demonstrated that a 1000 times higher Definity® dose is well-tolerated in primates86,87. 
Following these considerations, we assume that clinically approved microbubble doses may be suitable 
to administer a sufficient doxorubicin dose. Moreover, as we were able to significantly improve the 
cytotoxic effects on spheroid cells by loading the DOX-liposomes onto the microbubbles compared to 
DOX-liposomes alone (figure 9 and 11), we hypothesize that the doxorubicin concentration 
administered to the patient could be reduced, while maintaining clinical effects.  
While in this work thermosensitive liposomes were primarily used to study the fate of the released 
doxorubicin from the DOX-liposome patches, the use of ThermoDOX® for ultrasound-triggered 
treatments holds great potential as well. ThermoDOX® liposomes combined with high intensity 
focused ultrasound (HIFU) are currently clinically evaluated88, since a local hyperthermia to release the 
drugs can be induced by ultrasound at the appropriate radiation parameters. As such, we could 
envision a treatment protocol where a set of ultrasound pulses would be successively applied to allow 
a local drug delivery by sonoprinting, thereby increasing the drug dose at the target site, followed by 





In this study we have demonstrated that nanoparticle-loaded microbubbles exposed to ultrasound can 
locally deposit the nanoparticles onto the outer layers of 3D mono- and cospheroids. This ultrasound-
triggered delivery can be attributed to sonoprinting, which only occurs when nanoparticles are loaded 
onto the microbubble surface. We showed that doxorubicin-loaded liposomes could be successfully 
sonoprinted on the surface of tumor spheroids. Following sonoprinting, doxorubicin was released from 
the superficial liposomal patches, penetrated in the spheroids and exerted its cytotoxic effect. In 
summary, sonoprinting holds great promise to improve the intratumoral delivery of 
chemotherapeutics whose use is often limited by off-target effects. Future work will therefore focus 
on exploring its potential for in vivo drug delivery.   
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Supplementary Table 1: average size and PdI of different liposomes, as determined by DLS. 
 AVERAGE SIZE (NM) PDI 
REGULAR + DID 119 0,316 
REGULAR + DOX 199 0,189 
REGULAR + DOX + DID 210 0,238 
THERMO + DOX 202 0,326 






Supplementary Figure 1: Histograms corresponding to flow intensity scatter plots represented in figure 7. Doxorubicin 
fluorescence after treatment with (A-E) regular and (B-F) thermosensitive liposomes in (A-B) monospheroids and (E-F) 
cospheroids, and liposomal fluorescence after treatment with (C-G) regular and (D-H) thermosensitive liposomes in (C-D) 
monospheroids and (G-H) cospheroids DOX = doxorubicin; LIP = DOX-liposomes; MB = microbubbles; US = ultrasound; LIP + 
MB + US = DOX-liposomes and microbubbles coadministered before ultrasound radiation; LIP-MB + US = DOX-liposomes 




Supplementary Figure 2: Confocal images of 10 µm cryosections of (A-E) monospheroids and (F-J) cospheroids treated with 
controls: (A&F) DOX only; (B&G) regular or (C&H) thermosensitive DOX-liposomes only; (D&I) regular or (E&J) 
thermosensitive DOX-liposomes coadministered with microbubbles and exposed to ultrasound. Blue = DAPI, orange = 





Supplementary Figure 3: Individual fluorescence channels of confocal images depicted in figure 7D,E,H,I. From left to right: 
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